Male LUTS
Red Flags — act before continuing history
| Red flag | Why dangerous | Action |
|---|---|---|
| Visible (macroscopic) haematuria | Bladder cancer until proven otherwise. Renal cell carcinoma may also present with painless haematuria. The most common cause in a 60-year-old man is urothelial carcinoma. Never attribute to BPE alone. | Same-day 2WW urology |
| Complete inability to pass urine (acute urinary retention) | Acute urinary retention is a urological emergency. Bladder volume may exceed 1L. Causes: BPE, clot retention, post-operative, cold weather, medication. Requires immediate catheterisation. Delay risks detrusor decompensation and acute kidney injury. | A&E same-day |
| Loin pain + oliguria/anuria + bilateral hydronephrosis | Obstructive uropathy from BPE causing bilateral ureteric obstruction and acute kidney injury. Post-renal AKI — serum creatinine often dramatically elevated. Requires emergency decompression (catheter or nephrostomy). | 999 / A&E |
| New bone pain + weight loss + LUTS (possible metastatic prostate cancer) | Axial bone pain (spine, pelvis, ribs) + LUTS in an older man = prostate cancer with bone metastases until proven otherwise. PSA may be markedly elevated. Spinal cord compression can occur: early detection is limb-saving. | Same-day 2WW + urgent PSA |
| Leg weakness + perineal numbness + urinary/faecal retention (cauda equina) | Cauda equina syndrome from spinal cord compression by vertebral metastasis (prostate cancer) or central disc prolapse. Bilateral leg weakness, saddle anaesthesia, and loss of bladder/bowel control = neurosurgical emergency. Delay causes permanent paralysis. | 999 / immediate neurosurgery |
| Recurrent UTIs with LUTS | Recurrent UTIs in a man (2+ episodes/year) are always abnormal and require investigation. Causes include BPE with high PVR, bladder stones, renal tract abnormalities, or bladder cancer. Never treat recurrent male UTIs without investigation. | Urgent urology + imaging |
Safeguarding Considerations — Consider in Every Consultation
👴 Older Adults / Neglect
- Late presentation with severe retention may indicate carer-related neglect
- Check whether the patient is being helped to access toileting and fluid intake
- Dehydration from fluid restriction to avoid incontinence is a safeguarding concern
- Cognitive impairment: consider capacity for medication concordance
- Refer to adult safeguarding if neglect is suspected
🧒 Young Men / STI / Abuse
- LUTS in men under 40 is uncommon — always exclude STI (gonorrhoea, chlamydia) causing urethritis
- Unexplained dysuria or urethral discharge in a young man = STI screen at GUM
- Any urinary symptoms following assault should trigger sensitive safeguarding enquiry
- Prostate-related symptoms in men under 50 are unusual — investigate fully
🏠 Domestic Situation & Carer Impact
- Nocturia disrupting a partner's sleep can create relationship tension and carer burden
- Male reluctance to seek help may be driven by a desire not to “burden” family
- Social isolation from fear of incontinence is a mental health risk
- Ask: “Who else at home is this affecting?” — this often opens the door to wider concerns
💥 Mental Health & Medication Misuse
- Antipsychotics (clozapine), tricyclic antidepressants, and opioids all worsen LUTS
- LUTS in men with severe mental illness may be underdiagnosed and undertreated
- Alcohol misuse is both a bladder irritant and a sign of wider social problems
- Self-neglect in men with depression or addiction is a safeguarding concern
😴 Sleep Disruption and Fatigue
Nocturia >2/night causes sleep fragmentation, reduces REM sleep, and leads to chronic fatigue, cognitive impairment, and reduced reaction times. Men with significant nocturia have higher rates of depression, falls, and road traffic accidents.
“How is the sleep disruption affecting you during the day — is it affecting your energy, your mood, or your ability to drive or concentrate?”Management change: Severe nocturia driving significant daytime impairment raises treatment urgency; consider 24-hour urine diary to distinguish nocturnal polyuria from BPE-driven nocturia; driving safety conversation if severe.
🚶 Social Isolation and Restriction
Fear of urgency or inability to find a toilet in time leads men to restrict social activities, avoid long journeys, decline social invitations, and give up hobbies. Some stop drinking in public settings to control symptoms, leading to dehydration which paradoxically worsens LUTS.
“Have your urinary symptoms stopped you doing anything you used to enjoy — activities, outings, or seeing people?”Management change: Social restriction despite mild IPSS score = high bother, warrants active treatment regardless of score threshold; bladder retraining and urge suppression techniques are first-line.
💋 Sexual Function and Relationships
LUTS and erectile dysfunction (ED) share common aetiology (pelvic vascular insufficiency, autonomic neuropathy). Up to 50% of men with moderate–severe LUTS have co-existing ED. 5-ARIs (finasteride/dutasteride) cause ejaculatory dysfunction in ~5–8% and reduced libido in ~3%. These effects must be disclosed pre-treatment.
“Have your urinary symptoms affected your sexual life at all — either your ability to have sex, or your relationship with your partner?”Management change: Significant co-existing ED → tadalafil 5mg daily treats both LUTS and ED simultaneously; avoid 5-ARIs in men highly concerned about sexual function.
💼 Occupational and Practical Impact
Men who drive professionally (HGV, taxi), work in environments with restricted toilet access (surgeons, teachers, construction workers), or are in roles requiring sustained attention (pilots, executives) may find even mild LUTS severely restricts their working life.
“Are your urinary symptoms affecting your work in any way — or your ability to drive long distances?”Management change: Occupational LUTS impact justifies active treatment even with mild IPSS; bladder diary confirms occupational pattern; consider if DVLA notification required for severe retention risk.
😮 Cancer Anxiety and Health Beliefs
Men with LUTS carry an enormous unspoken cancer anxiety. Online self-diagnosis has increased fear. Men who have seen relatives or friends die from prostate cancer present with significantly higher anxiety. Some men delay consulting precisely because they fear the diagnosis.
“I get the sense from what you said that cancer has been on your mind — is that right? Tell me more about that worry.”Management change: Unaddressed cancer anxiety impairs concordance with conservative management; men who fear cancer will not engage with “watchful waiting” unless the cancer concern is explicitly and specifically addressed first.
🍺 Lifestyle Factors Worsening LUTS
Obesity increases intra-abdominal pressure, worsening voiding symptoms. Sedentary lifestyle reduces pelvic floor tone. Excess caffeine and alcohol intake directly worsen LUTS. Poor fluid timing (large volumes in evenings) worsens nocturia. These are modifiable causes, not incidental lifestyle details.
“Tell me about your fluid habits — what do you drink, how much, and at what times of day? And how is your weight—has that changed recently?”Management change: Lifestyle modification is first-line for mild LUTS and an adjunct at all severities — caffeine restriction, fluid management, and weight loss can produce IPSS reductions equivalent to pharmacotherapy.
- Jumping straight to prostate examination without establishing symptom history
- Ordering PSA without pre-test counselling about implications
- Not asking the IPSS quality-of-life bother question
- Missing cancer anxiety — not naming or addressing it directly
- Ignoring the sexual function impact on the patient's relationship
- Failing to ask about medication causes (anticholinergics, decongestants)
999 or A&E Now
A&E / catheterise now- Acute urinary retentionComplete inability to pass urine + painful suprapubic distension. Catheterise immediately or send to A&E. Do not delay with investigations.
- Obstructive uropathy + AKIBilateral hydronephrosis, rising creatinine, oliguria. Emergency decompression required (urethral catheter or nephrostomy).
- Cauda equina syndromeBilateral leg weakness, saddle anaesthesia, bladder/bowel loss. 999. Emergency neurosurgery within hours. Delay causes permanent paralysis.
- Clot retention / haematuria with retentionUnable to void + clots in urine. Requires 3-way catheter irrigation. A&E same-day.
- Urosepsis (infected retention)Fever + rigors + retention + raised WBC. IV antibiotics + catheterisation + hospital admission. 999.
Days to 2 Weeks
2WW / urgent urology- Visible (macroscopic) haematuriaSame-day urgent 2WW referral to urology. Never attribute to BPE alone.
- PSA above age thresholdPSA >3 ng/mL at any age, or disproportionate to prostate size. 2WW prostate cancer referral. Discuss with patient before referring.
- Hard or irregular prostate on DRESuspicious DRE findings regardless of PSA level. 2WW prostate cancer referral. Prostate cancer can exist with normal PSA.
- New bone pain + LUTSPossible metastatic prostate cancer. Urgent PSA + 2WW. Spinal cord compression: immediate imaging.
- Recurrent UTIs in a manTwo or more UTIs in 12 months. Urgent urology for cystoscopy and upper tract imaging.
Manage in Primary Care
NICE CG97 pathway- IPSS ≤7 (mild LUTS)Watchful waiting + lifestyle modification. No pharmacotherapy needed unless bother score high.
- IPSS 8–19 (moderate LUTS)Lifestyle + pharmacotherapy (alpha-blocker if voiding dominant; antimuscarinic/mirabegron if storage dominant).
- Smooth enlarged prostate, normal PSABPE confirmed clinically. Medical management in primary care. Reassess at 4–6 weeks.
- Established BPE on monitoringAnnual PSA, IPSS reassessment. GP-led shared care with urology if patient on combination therapy or 5-ARI.
- Nocturia + nocturnal polyuria24-hour urine diary, fluid restriction, diuretic timing adjustment, desmopressin consideration.
- Missing acute retention as an emergency — sending home without catheterisation plan
- Failing to recognise haematuria as a 2WW trigger regardless of LUTS pattern
- Not mentioning cancer referral pathway when PSA is raised
- Failing to offer DRE in a new LUTS presentation
- Not explaining why DRE is needed before performing it
- Forgetting to check urine dipstick before prescribing
- Not measuring PVR when incomplete emptying is described
- Ordering PSA without explaining what a raised result might mean
- Not measuring PVR when incomplete emptying is described
- Omitting urine dipstick before prescribing alpha-blocker
- Not discussing prostate volume relevance when prescribing 5-ARI
“Your prostate gland — roughly the size of a walnut — sits right around the tube that carries urine from your bladder. As men age, it is very common for the prostate to gradually enlarge. When it does, it gently squeezes that tube, making it harder for urine to flow through freely. Think of it like slowly squeezing a garden hose — the water still comes through, but it takes more effort and the flow is weaker. This is called benign prostatic enlargement, or BPE. The word benign is important — it means it is not cancer. I know you were worried about that, and I want to be clear: the symptoms you are describing — gradual onset, weakening stream, waking at night — are the classic pattern of BPE, not prostate cancer. Now, prostate cancer can coexist with BPE, which is why we do the PSA blood test and prostate examination — but based on what I have found today, there is nothing to suggest cancer. Does that help to explain what is going on?”
“My father died of prostate cancer — I probably have it too.”
“Having a first-degree relative with prostate cancer does increase your risk, and that is exactly why I am taking your symptoms seriously and doing a PSA test. But having the same symptoms as your father does not mean you have the same diagnosis — BPE is far more common than prostate cancer and causes the same type of symptoms. Let me examine you properly and then we can have a much more informed conversation.”
“My friend had the same symptoms and needed an operation immediately.”
“Many men do need surgery at some point, but the good news is that there are effective tablets that work very well for most men and avoid the need for an operation altogether. We would usually try those first. Surgery is reserved for men where tablets have not helped enough, or where there is a specific problem that needs fixing. We are a long way from that at this point.”
Benign prostatic enlargement (BPE) / LUTS
Gradual-onset voiding + storage symptoms, smooth enlarged prostate on DRE, age-appropriate PSA, PVR <150 mL. Pharmacotherapy in primary care.
Overactive bladder (OAB)
Storage symptoms predominant (urgency, frequency, nocturia), normal uroflowmetry, no significant BOO. First-line: antimuscarinic or mirabegron.
Prostate cancer (localised)
Raised PSA >3 ng/mL and/or abnormal DRE. 2WW prostate cancer referral. Multi-parametric MRI then biopsy if MRI suspicious.
Urethral stricture
Fixed obstructive uropathy — prior catheterisation, urethral surgery, or STI. Not responsive to alpha-blockers. Urethrogram then urethrotomy/urethroplasty.
Acute urinary retention
Complete inability to void + painful distended bladder. Catheterise immediately or 999 if catheterisation not possible in practice setting.
Cauda equina syndrome
Spinal cord compression from vertebral metastasis or disc. Bilateral leg weakness + saddle anaesthesia + bladder/bowel dysfunction. 999 — neurosurgical emergency.
- Not addressing the cancer concern before explaining BPE
- Using the term “benign” without explaining what it means
- Not explaining the difference between BPE and prostate cancer clearly
- Dismissing the concern rather than directly and explicitly addressing it
- Making a 2WW referral without explaining what it means to the patient
- Attributing haematuria to BPE and not referring
- Sending a man in acute retention home without catheterisation
Validate — name their expectation
Men with LUTS often come expecting either reassurance (it is not cancer) or action (do something about my symptoms). Some expect a referral; some expect surgery. Some simply want someone to take their symptoms seriously after months of coping alone. Name the expectation before offering a plan.
“It sounds like you have been worried about this for a while — can I ask what you were hoping today's appointment might achieve for you?”Explain — share your clinical reasoning
Explain why watchful waiting is appropriate for mild symptoms (no harm from not treating; lifestyle measures can be very effective) versus why active treatment is recommended for moderate symptoms. Explain how tablets work and what improvement is realistic (IPSS reduction of 3 points = clinically meaningful).
“Based on your symptom score, I think a tablet called tamsulosin would help. It relaxes the muscles around the prostate, making it easier for urine to flow. About 70% of men notice a meaningful improvement within 4 to 6 weeks.”Negotiate — offer something today
Never leave a man with LUTS with no action plan. Even watchful waiting involves an action: a bladder diary, lifestyle changes, a 3-month review. Men who feel dismissed rather than supported often do not return until symptoms are severe.
“I would like to start you on a tablet today and see you in 4 to 6 weeks to see how much improvement you have had. In the meantime, I am going to give you some advice about fluids and caffeine that can also make a real difference.”Excessive fluid intake (especially in the evening) directly increases urine production and worsens nocturia. Under-hydration concentrates urine, causing bladder irritation and urgency. Optimal fluid distribution reduces urine production at night without reducing daytime function.
Prescribe a fluid diary. Target: 1.5–2L/day, spread evenly across the day. No large volumes in the 2 hours before bed. Elevate legs in the afternoon to reduce evening oedema redistribution that worsens nocturia.
Caffeine is a direct detrusor irritant and diuretic. 200mg caffeine (2 cups of coffee) measurably increases urgency and frequency within 1 hour of ingestion. Alcohol causes diuresis and reduces ADH release, worsening nocturia acutely.
Audit caffeine intake specifically: coffee, tea, cola, energy drinks, chocolate. Switch to decaffeinated alternatives. No alcohol after 8pm. The IPSS reduction from caffeine restriction alone is clinically meaningful in mild–moderate LUTS.
Detrusor overactivity causes urgency through uninhibited detrusor contractions. Bladder retraining uses cognitive and pelvic floor techniques to override the urgency signal, progressively increasing the interval between voids and increasing functional bladder capacity.
Start by voiding every 90 minutes whether or not urgency is felt. Extend by 15 minutes per week. Urgency suppression technique: squeeze pelvic floor, distract attention, wait for urgency to pass, then walk (not rush) to toilet. Refer to continence nurse for structured programme.
Obesity (BMI >30) increases intra-abdominal pressure, worsening voiding symptoms. Adipose tissue contains aromatase, converting androgens to oestrogens, which stimulates prostatic stromal growth. Physical activity improves pelvic floor tone and reduces systemic inflammation linked to LUTS.
Even a 5–10% weight loss produces clinically meaningful IPSS reduction. Walking 30 minutes daily is sufficient. Refer to NHS weight management programme or exercise on prescription scheme. Pelvic floor exercises are evidence-based for post-void dribbling.
Loop diuretics (furosemide) and thiazides cause a diuretic peak 2–4 hours after dosing. If taken in the evening, this peak coincides with sleep onset, dramatically worsening nocturia. Shifting the dose to morning or early afternoon eliminates this pharmacological cause of nocturia without changing the drug.
Review ALL diuretics and their timing. Move furosemide to before midday where clinically safe. For men on twice-daily diuretics, consider concentrating the larger dose in the morning. This simple intervention can reduce nocturia by 1–2 voids per night.
Symptom diaries reveal patterns invisible in clinical assessment: nocturnal polyuria (oedema redistribution), functional bladder capacity, timing of urgency episodes, and relationship between fluid intake and symptoms. They are diagnostic tools, not just patient education.
Provide a printed or app-based voiding diary (time of each void, volume, urgency score 0–4, leakage). Analyse at follow-up: nocturnal polyuria pattern → desmopressin consideration; small-volume frequent voids → OAB; large volumes → polyuria (glucose, DI).
Tamsulosin 400 mcg OD (or alfuzosin 10mg OD SR) — first-line pharmacotherapy
- Mechanism: alpha-1A receptor blockade in prostate → smooth muscle relaxation → improved flow
- Onset of action: 24–48h (most benefit within 2 weeks)
- Symptomatic improvement in ~70% of men; IPSS reduction ~3–5 points
- Take at bedtime initially to reduce first-dose dizziness
- Warn about IFIS if cataract surgery planned — inform ophthalmologist
Finasteride 5mg OD (or dutasteride 500 mcg OD)
- Mechanism: 5-alpha reductase inhibition → reduces DHT → prostate shrinkage (~20–30% over 6 months)
- Benefit threshold: prostate volume >30 mL OR PSA >1.4 ng/mL
- Reduces prostate cancer risk by ~25% (PCPT trial — but does not eliminate it)
- Reduces PSA by ~50% after 6 months — must double PSA value for cancer surveillance
- Takes 3–6 months for full symptom benefit — do not stop early
Mirabegron 50mg OD (preferred) or solifenacin 5mg OD
- Mirabegron: beta-3 agonist, relaxes detrusor → reduces urgency/frequency. No anticholinergic effects. Safe in glaucoma and prostate. Monitor BP (mild pressor effect).
- Solifenacin: muscarinic antagonist, reduces detrusor overactivity. Dry mouth and constipation common. CAUTION: avoid if PVR >150 mL or glaucoma.
- Never add antimuscarinic before ensuring PVR is acceptable — risk of precipitating retention in BPE
Tadalafil 5mg daily treats both LUTS and erectile dysfunction simultaneously.
- PDE5 inhibitor → increased smooth muscle relaxation in prostate, bladder neck, and penile vasculature
- NICE approved for LUTS in men who also have ED — dual benefit
- IPSS improvement ~3 points; IIEF (erectile function) improvement significant
- Do NOT combine with alpha-blockers (hypotension risk) or nitrates (severe hypotension)
- Caution in cardiovascular disease — check sexual activity is safe
Desmopressin for nocturnal polyuria (>33% of urine output at night)
- Synthetic ADH analogue → reduces urine production at night by ~30–50%
- Only use if nocturnal polyuria confirmed on 3-day bladder diary
- Desmopressin 120–240 mcg sublingual at bedtime (or 200 mcg oral)
- CONTRAINDICATED: hyponatraemia history, heart failure, CKD (eGFR <50), age >65 with high fall risk
- Check Na+ at 3 days, 1 month, then 3-monthly — hyponatraemia risk is significant
Select patient characteristics — LUTS drug recommendation appears below
“Take this tablet at bedtime for the first week to reduce any dizziness. You should notice an improvement in your urinary flow within 2 weeks. One thing to mention: some men notice that when they ejaculate, less fluid comes out — this is harmless and happens in about 1 in 10 men on this tablet.”
SCA pearl: A patient on tamsulosin mentions he is having cataract surgery next month. Always ask about planned cataract surgery before prescribing tamsulosin — IFIS (intraoperative floppy iris syndrome) can cause serious operative complications. Inform the ophthalmologist proactively.
“This tablet will gradually shrink your prostate over the next 6 months — think of it as a long-term investment. However, it can affect sexual function in a small number of men, so I want to discuss that with you before you start. It also halves your PSA level, which is important for how we interpret future PSA tests — we simply multiply your PSA result by two to get an accurate reading.”
SCA pearl: A patient on finasteride for 6 months has a PSA of 1.8 ng/mL. The “true” PSA equivalent is 3.6 ng/mL — above the 3 ng/mL 2WW threshold. Always double the PSA in any man on a 5-ARI for ≥6 months. Failure to do so risks missing prostate cancer.
“I am prescribing two tablets together. The first works within days to improve your urine flow. The second takes 3 to 6 months to gradually shrink the prostate and reduce the risk of you needing a catheter in the future. They work best together. Do not stop either without telling us first.”
SCA pearl: A patient on combination therapy for 1 year asks if he can stop the finasteride because it is affecting his sex life. Explain that stopping 5-ARI without the alpha-blocker may cause rapid symptom relapse and increases retention risk. Offer sexual dysfunction review — symptoms often improve; if persistent, PDE5 inhibitor can help co-existing ED.
“This tablet reduces the overactivity of your bladder muscle, which is what is causing the urgency. The most common side effect is a dry mouth — keeping a small water bottle handy can help. It is important that you continue taking it regularly for at least 4 to 6 weeks before we assess whether it is working.”
SCA pearl: Never prescribe an antimuscarinic in a man with LUTS without first measuring PVR and confirming it is <150 mL. A man with BPE + high PVR who is given solifenacin without PVR measurement can go into acute urinary retention within days. This is a commonly tested SCA clinical error.
“This tablet works differently from antimuscarinics — it relaxes the bladder muscle without the dry mouth or constipation side effects most people find difficult. It takes 4 to 6 weeks to get the full benefit. It can slightly raise your blood pressure, so we will check that at your next review.”
SCA pearl: A patient with BPH and OAB who is on tamsulosin still has urgency. Before adding an antimuscarinic, always measure PVR. If PVR is acceptable (<150 mL), consider mirabegron as the preferred add-on rather than solifenacin — lower risk of precipitating retention, better tolerated, no anticholinergic cognitive burden.
“This is a daily low-dose tablet that works on both your urinary symptoms and your erectile function simultaneously. The most important safety point: you must never take this if you are also using GTN spray or angina tablets — the combination can cause a dangerous drop in blood pressure.”
SCA pearl: Before prescribing tadalafil for LUTS, always check: (1) Is the patient on nitrates? (2) Is the patient on alpha-blockers? (3) Is his cardiovascular status stable enough for sexual activity? Failure to ask about nitrates is the most commonly failed SCA point in a LUTS + ED consultation.
Sleep Disruption and Fatigue
Nocturia >2/night causes sleep fragmentation, reduces REM sleep, and produces chronic fatigue, cognitive impairment, and irritability. The sleep impact of LUTS is often more bothersome than the urinary symptoms themselves.
Men with significant nocturia have higher rates of depression, road traffic accidents (due to daytime sleepiness), and falls (nighttime trips to the toilet in the dark).
DVLA notification is not routinely required for LUTS, but severe daytime sleepiness impairing driving should be discussed directly with the patient.
“The most important thing to me is that we get your sleep back — how would it feel to be waking just once or not at all?”Social Restriction and Planning
Fear of urgency or poor access to toilets leads men to restrict social activities: avoiding long car journeys, refusing invitations to events or restaurants without easy toilet access, and withdrawing from activities they previously enjoyed.
Some men restrict fluid intake to manage symptoms, leading to dehydration which paradoxically worsens urgency and increases UTI risk.
Social isolation from LUTS is a significant mental health risk, particularly in older men who may already have limited social networks.
“Have you had to change any of your plans or activities because of your bladder — journeys, social events, sports?”Sexual Function and Relationships
LUTS and ED share common aetiology (pelvic vascular and autonomic dysfunction). Up to 50% of men with moderate–severe LUTS have co-existing ED. Nocturia disrupts sleep and reduces sexual desire.
Treatment effects on sexual function must be disclosed: tamsulosin causes retrograde ejaculation in ~10%; finasteride causes reduced libido and ejaculatory dysfunction in ~5–8%. These effects are reversible on stopping but some persist.
Partners are profoundly affected by the man's LUTS — both by the disrupted sleep and by changes in sexual function and intimacy.
“I always ask about sexual function in this context because the treatment options can affect it — is that something I can ask you about?”Driving and Occupational Impact
LUTS does not generally require DVLA notification unless it causes severe incontinence or distracting urgency that impairs driving concentration. However, men should be asked directly whether urgency has caused dangerous driving situations.
Professional drivers (HGV, taxi), healthcare workers (theatre, procedures), teachers, and men in roles without easy toilet access may find even mild LUTS severely restricts their working function.
Nocturia-related daytime fatigue is a significant driving safety concern — men may be falling asleep at the wheel but attribute it to “getting older.”
“Does your work or driving involve situations where you need to hold on for long periods? Has that become difficult?”Cancer Anxiety and Ongoing Uncertainty
Even after a negative workup, cancer anxiety persists in many men with LUTS — particularly those with a family history of prostate cancer or who have had a slightly elevated PSA that proved benign.
Annual PSA surveillance can perpetuate anxiety if not properly contextualised. Men need to understand that BPE monitoring is routine and protective, not a sign of ongoing suspicion.
If cancer is subsequently diagnosed, psychological support needs are significant. GP is often the first point of contact after a diagnosis and must be prepared for the emotional response.
“I know cancer was on your mind at the beginning — has what we discussed today put your mind at rest, or do you still have concerns?”Medication Impact and Long-Term Treatment
Men on long-term LUTS medication often experience “treatment fatigue” — reducing or stopping medication without telling their doctor, often because of sexual side effects they feel embarrassed to report.
5-ARI sexual side effects (reduced libido, ejaculatory dysfunction) may not be disclosed unless specifically asked. Men may stop finasteride secretly, leading to rapid prostate regrowth and symptom relapse.
Managing expectations about medication duration (“this is likely a long-term prescription, not a course”) and inviting open discussion about side effects at every review significantly improves adherence.
“Some men find these tablets affect their sexual function — I always like to check at each visit whether that has been an issue for you.”Immediate (at presentation) — New LUTS Assessment
IPSS questionnaire, urine dipstick, blood pressure, DRE offered (with explanation), bladder scan PVR, PSA offered with informed consent counselling. Start alpha-blocker if IPSS 8+ and no contraindication. Bladder diary prescribed. Safety-net for acute retention.
4–6 weeks — Alpha-Blocker Response Check
Repeat IPSS — meaningful response = ≥3 point reduction. Review bladder diary. Check PSA result and discuss implications. If IPSS not improved and prostate >30 mL: add finasteride/dutasteride. If storage symptoms persist: consider mirabegron. Blood pressure review.
3 months — 5-ARI Efficacy Check
Repeat IPSS — 5-ARI takes 3–6 months for full benefit. PSA re-check: document that PSA will be halved after 6 months. Sexual function review (5-ARI side effects). If no improvement with two drug classes: urology referral. Reinforce lifestyle modification adherence.
6 months — Establish Baseline on Dual Therapy
PSA now halved from 5-ARI effect — document adjusted PSA and update patient. IPSS comparison with baseline. PVR reassessment. If IPSS <8 and patient comfortable: step down to annual review. If severe (≥20) despite dual therapy: urology referral for surgery consideration.
Annual — Ongoing Shared Care Review
Annual IPSS, PSA (doubled if on 5-ARI), urine dipstick, blood pressure, PVR if symptomatic deterioration. Medication review (side effects, concordance). Sexual function review. Cancer anxiety check. Vaccination: influenza, pneumococcal (age-appropriate). Ask about acute retention episodes since last review.
Memory rule
At every review, check the IPSS (has it reduced by ≥3 points?), the PSA (remember to double if on 5-ARI for ≥6 months), and a PVR if incomplete emptying or worsening voiding symptoms. Add a urine dipstick and blood pressure. Never assume stability — BPE can progress unpredictably and acute retention can occur without warning even in patients on treatment.
⚠ Three scenario-specific phrases — use these verbatim
Why safety-netting matters beyond clinical care in male LUTS
- Not naming retention as the specific emergency requiring A&E
- Failing to mention the 4–6 week IPSS review as a specific follow-up
- Not checking in on whether the cancer anxiety has been addressed
- Discussing tadalafil without asking about nitrates first
- Prescribing 5-ARI without disclosing sexual side effects
- Skipping the closing question
- IPSS formally assessed or all 7 domains covered systematically
- DRE offered with explanation of what it assesses and why
- PSA offered with balanced pre-test counselling (pros and cons)
- PVR measurement planned or performed
- Diagnosis explained in plain language with garden hose analogy or equivalent
- Correct first-line drug selected with dose, onset, and side effects
- Acute retention safety-net: named specifically, not generic
- Cancer concern named and directly and specifically addressed
- Patient's ideas about LUTS cause elicited
- Expectations for today's appointment explored and met or negotiated
- Embarrassment validated without being made worse
- PSA counselling given collaboratively — patient's choice respected
- Sexual function discussed sensitively before prescribing 5-ARI or tadalafil
- Closing question asked
Who you are
Mr David Okafor, 62. Retired engineer. Married, three adult children. Generally fit and well — known hypertension on amlodipine 5mg OD. Non-smoker. Drinks 2–3 units alcohol per week. Semi-active — walks regularly. Wife encouraged him to attend. Has had symptoms for about 6 months but delayed coming because he was worried about what they might mean.
Hidden agenda
Primary hidden agenda: His father died of prostate cancer aged 65. David is convinced he has it too and has been delaying the appointment partly out of fear of finding out. He has not told his wife about this fear because he does not want to worry her. He desperately wants reassurance but also fears it will be false reassurance.
Secondary hidden agenda: He read online about finasteride causing erectile dysfunction and is secretly worried about starting any treatment that affects his sexual function. He and his wife still have an active sexual relationship and this matters greatly to him. He will not volunteer this unless asked directly and sensitively.
Symptoms if asked directly (IPSS ~14)
- Nocturia: 3–4 times per night (most bothersome symptom)
- Weak stream: yes, noticeably weaker for 6 months
- Incomplete emptying: yes, often feels the bladder has not fully emptied
- Straining: mild, sometimes needs to push
- Frequency: around every 2 hours during the day
- Urgency: mild, can usually wait
- Intermittency: yes, stream stops and starts occasionally
- QoL bother score: 4/6 (“mostly dissatisfied”)
- No haematuria, no bone pain, no weight loss
- No acute retention episodes
Lifestyle + useful details
- Drinks approximately 3 cups of coffee per day (mentions this if fluid habits are explored)
- Has a large glass of water before bed “because he read it was healthy” — this is worsening nocturia
- On amlodipine — has ankle swelling which is reabsorbed at night (worsens nocturia)
- Not on any other regular medications, no OTC decongestants
- Had one uncle (paternal) who had a TURP in his 70s — is worried this will happen to him
Resolution: David accepts the management plan if the candidate: (1) directly and specifically addresses the prostate cancer concern — does not dismiss it but explains why the symptom pattern and examination findings make BPE more likely than cancer, and why PSA plus DRE will give a much clearer picture; (2) acknowledges the significance of his father's death; (3) explains the DRE and PSA clearly so David feels investigated rather than fobbed off; (4) asks (sensitively) about sexual function before prescribing, giving David the opportunity to raise his finasteride concern; and (5) gives a specific named follow-up plan with IPSS reassessment at 4–6 weeks.
- Acute urinary retention (cannot void + painful bladder)
- Obstructive uropathy + rising creatinine
- Cauda equina (leg weakness + saddle anaesthesia)
- Clot retention / urosepsis
- Visible haematuria — 2WW bladder cancer
- PSA >3 ng/mL — 2WW prostate cancer
- Hard/irregular prostate on DRE — 2WW
- New bone pain + LUTS (metastatic PCa?)
- PVR >300 mL (catheterise + urgent urology)
- IPSS ≤7: watchful waiting + lifestyle
- IPSS 8–19: pharmacotherapy trial
- Smooth enlarged prostate, normal PSA
- Established BPE on annual monitoring
| Test | Indication | Timing | Action threshold |
|---|---|---|---|
| IPSS | Treatment response | 4–6 wks, 3m, then annually | <3 point reduction → step up or refer to urology |
| PSA | Cancer surveillance | At diagnosis; annually | >3 ng/mL or >0.75 rise/year → 2WW. Double if on 5-ARI ≥6m. |
| PVR | Bladder emptying safety | Baseline; repeat if worsening | >300 mL → catheterise + urgent urology; >150 mL → consider referral |
| Blood pressure | Alpha-blocker / tadalafil | Baseline; 4–6 weeks | Symptomatic hypotension → reduce dose; switch to tamsulosin OCAS |
| Renal function | Obstructive uropathy | Baseline; annually if high PVR | Rising creatinine + LUTS → upper tract ultrasound + urgent urology |
| Sexual function | 5-ARI / alpha-blocker SE | 6 months, then annually | Persistent dysfunction → review 5-ARI; consider tadalafil for co-existing ED |